Significantly higher rates of AKI were observed in those treated with TKI/anti-VEGF, (p = 0.01), any chemotherapy within 60 days, CHF, CKD, AKI, brain and other nervous system tumors, leukemia, lymphoma, male genital system, myeloma, oral cavity and pharynx tumors, respiratory system tumors (all p < 0.001), digestive system and female genital system tumors (all p = 0.01). The gene discussed is VEGFA; the disease is plasma cell myeloma.